Capricor CEO won’t rule out legal action against FDA after negative adcomm
AdComnegativeNegative
AI Analysis
Summary
Capricor's DMD cardiomyopathy drug received a negative 9-3 advisory committee vote, with the CEO considering legal action against the FDA citing allegations of biased intentions.
Outcome Details
Advisory committee voted 9-3 against recommending approval
Importance:8/10
Sentiment:
-0.95
FDAadvisory committeerejectionDuchenne muscular dystrophylegal actionregulatory setback
Related Companies
Read the original article
Published by BioSpace on July 31, 2026 6:42 PM